The impact of hypnotic use on the association between insomnia and breast cancer risk remains unclear. This study examined whether insomnia increases the aforementioned risk and explored the effects of hypnotic use on this relationship.
Materials and Methods:
This retrospective cohort study was conducted using data retrieved from the Longitudinal Health Insurance Research Database 2010. In total, 11,021 patients with insomnia, who were categorized by hypnotic use and nonuse, were identified; 22,042 age-matched participants without insomnia were then randomly selected. Cox proportional hazards regression was used for the analyses.
Results:
The insomnia cohort had a higher risk of breast cancer than did the control cohort (adjusted hazard ratio [aHR] = 1.43; 95% confidence interval [CI] = 1.10–1.84). The aHR was 1.09 for insomniac with hypnotics use, 1.41 for insomniac without hypnotics use, and 0.71 for hypnotics users without insomnia (95% CIs = 0.71–1.68, 1.07–1.85, and 0.40–1.27) compared with those individuals without insomnia who did not use hypnotics.
Conclusion:
This nationwide population-based cohort study reveals that insomnia but not hypnotic use is associated with an increased risk of breast cancer.
Get full access to this article
View all access options for this article.
References
1.
OhayonMM. Prevalence of DSM-IV diagnostic criteria of insomnia: Distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res, 1997; 31:333–346.
2.
Ancoli-IsraelS, RothT. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I. Sleep, 1999; 22Suppl 2:S347–S353.
3.
National Institutes of Health. National Institutes of Health State of the Science Conference statement on manifestations and management of chronic insomnia in adults, June 13–15, 2005. Sleep, 2005; 28:1049–1057.
4.
BaglioniC, BattaglieseG, FeigeB, et al.Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord, 2011; 135:10–19.
5.
BolgeSC, DoanJF, KannanH, BaranRW. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res, 2009; 18:415–422.
6.
VgontzasAN, LiaoD, PejovicS, CalhounS, KaratarakiM, BixlerEO. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care, 2009; 32:1980–1985.
7.
FangHF, MiaoNF, ChenCD, SitholeT, ChungMH. Risk of cancer in patients with insomnia, parasomnia, and obstructive sleep apnea: A nationwide nested case–control study. J Cancer, 2015; 6:1140–1147.
FanL, Strasser-WeipplK, LiJJ, et al.Breast cancer in China. Lancet Oncol, 2014; 15:e279–e289.
10.
DeSantisCE, FedewaSA, Goding SauerA, KramerJL, SmithRA, JemalA. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016; 66:31–42.
11.
PierobonM, FrankenfeldCL. Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res Treat, 2013; 137:307–314.
12.
WoosterR, BignellG, LancasterJ, et al.Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995; 378:789–792.
13.
KeyTJ, ApplebyPN, ReevesGK, et al.Sex hormones and risk of breast cancer in premenopausal women: A collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol, 2013; 14:1009–1019.
14.
ChlebowskiRT, MansonJE, AndersonGL, et al.Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst, 2013; 105:526–535.
15.
SavvidisC, KoutsilierisM. Circadian rhythm disruption in cancer biology. Mol Med, 2012; 18:1249–1260.
16.
BlakemanV, WilliamsJL, MengQJ, StreuliCH. Circadian clocks and breast cancer. Breast Cancer Res, 2016; 18:89.
17.
GeryS, VirkRK, ChumakovK, YuA, KoefflerHP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene, 2007; 26:7916–7920.
18.
KhawajaA, RaoS, LiL, ThompsonCL. Sleep duration and breast cancer phenotype. J Cancer Epidemiol, 2013; 2013:467927.
19.
DavisS, MirickDK, StevensRG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst, 2001; 93:1557–1562.
20.
StevensRG, ReaMS. Light in the built environment: Potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control, 2001; 12:279–287.
LegerD, LaudonM, ZisapelN. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med, 2004; 116:91–95.
23.
RiemannD, KleinT, RodenbeckA, et al.Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Res, 2002; 113:17–27.
24.
VogtmannE, LevitanEB, HaleL, et al.Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. Sleep, 2013; 36:1437–1444.
25.
HorrobinDF, TroskoJE. The possible effect of diazepam on cancer development and growth. Med Hypotheses, 1981; 7:115–125.
26.
IqbalU, NguyenPA, Syed-AbdulS, et al.Is long-term use of benzodiazepine a risk for cancer?. Medicine, 2015; 94:e483.
27.
KarmaliRA, VolkmanA, MuseP, LouisTM. The influence of diazepam administration in rats bearing the R3230AC mammary carcinoma. Prostaglandins Med, 1979; 3:193–198.
28.
KripkeDF, LangerRD, KlineLE. Hypnotics' association with mortality or cancer: A matched cohort study. BMJ Open, 2012; 2:e000850.
29.
ChenPL, LeeWJ, SunWZ, OyangYJ, FuhJL. Risk of dementia in patients with insomnia and long-term use of hypnotics: A population-based retrospective cohort study. PLoS One, 2012; 7:e49113.
30.
ShenCC, YangAC, HungJH, HuLY, TsaiSJ. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist, 2015; 20:45–49.
31.
ZhangY, CooganPF, PalmerJR, StromBL, RosenbergL. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: The case–control surveillance study revisited. Am J Epidemiol, 2005; 162:165–170.
32.
TerryMB, GammonMD, ZhangFF, et al.Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA, 2004; 291:2433–2440.
33.
KohWP, YuanJM, SunCL, et al.Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res, 2003; 63:573–578.
34.
Van FossenVL, WilhelmSM, EatonJL, McHenryCR. Association of thyroid, breast and renal cell cancer: A population-based study of the prevalence of second malignancies. Ann Surg Oncol, 2013; 20:1341–1347.
35.
SiniV, CinieriS, ConteP, et al.Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. Crit Rev Oncol Hematol, 2016; 100:57–58.
36.
RosenbaumPR, RubinDB. The central role of the propensity score in observational studies for causal effects. Biometrika, 1983; 70:41–55.
37.
BoyleP, BoniolM, KoechlinA, et al.Diabetes and breast cancer risk: A meta-analysis. Br J Cancer, 2012; 107:1608–1617.
38.
YuKH, KuoCF, HuangLH, HuangWK, SeeLC. Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases: A nationwide population-based dynamic cohort study in Taiwan. Medicine, 2016; 95:e3540.
39.
HowellA, EvansGD. Hormone replacement therapy and breast cancer. Recent Results Cancer Res, 2011; 188:115–124.
40.
YangYS, KorneliusE, ChiouJY, et al.Low-dose aspirin reduces breast cancer risk in women with diabetes: A nationwide retrospective cohort study in Taiwan. J Womens Health (Larchmt), 2017; 26:1278–1284.
41.
GanzPA, HabelLA, WeltzienEK, CaanBJ, ColeSW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res Treat, 2011; 129:549–556.
42.
NielsenSM, WhiteMG, HongS, et al.The breast-thyroid cancer link: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2016; 25:231–238.
43.
McPhersonK, SteelCM, DixonJM. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ, 2000; 321:624–628.
44.
LiuK, HeL, TangX, et al.Relationship between menopause and health-related quality of life in middle-aged Chinese women: A cross-sectional study. BMC Women's Health, 2014; 14:7.
45.
StevensRG, DavisS. The melatonin hypothesis: Electric power and breast cancer. Environ Health Perspect, 1996; 104Suppl 1:135–140.
46.
CosS, MediavillaMD, FernandezR, Gonzalez-LamunoD, Sanchez-BarceloEJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?. J Pineal Res, 2002; 32:90–96.
47.
WallaceRB, ShermanBM, BeanJA. A case–control study of breast cancer and psychotropic drug use. Oncology, 1982; 39:279–283.
48.
HalapyE, KreigerN, CotterchioM, SloanM. Benzodiazepines and risk for breast cancer. Ann Epidemiol, 2006; 16:632–636.
49.
RosenbergL, PalmerJR, ZauberAG, et al.Relation of benzodiazepine use to the risk of selected cancers: Breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin's lymphoma, testis, Hodgkin's disease, thyroid, and liver. Am J Epidemiol, 1995; 141:1153–1160.
50.
FolkerdE, DowsettM. Sex hormones and breast cancer risk and prognosis. Breast, 2013; 22Suppl 2:S38–S43.
51.
Endogenous Hormones, Breast Cancer Collaborative Group, KeyTJ, et al.Circulating sex hormones and breast cancer risk factors in postmenopausal women: Reanalysis of 13 studies. Br J Cancer, 2011; 105:709–722.
52.
SantoroN, RandolphJF. Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am, 2011; 38:455–466.
53.
KeyT, ApplebyP, BarnesI, ReevesG, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst, 2002; 94:606–616.
54.
Endogenous Hormones and Breast Cancer Collaborative Group. Sex hormones and breast cancer risk in premenopausal women: Collaborative reanalysis of seven prospective studies. Lancet Oncol, 2013; 14:1009–1019.
55.
CheraghiZ, PoorolajalJ, HashemT, EsmailnasabN, Doosti IraniA. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. PLoS One, 2012; 7:e51446.
56.
JungS, WangM, AndersonK, et al.Alcohol consumption and breast cancer risk by estrogen receptor status: In a pooled analysis of 20 studies. Int J Epidemiol, 2015; 45: 916–928.
57.
GaudetMM, GapsturSM, SunJ, DiverWR, HannanLM, ThunMJ. Active smoking and breast cancer risk: Original cohort data and meta-analysis. J Natl Cancer Inst, 2013; 105:515–525.
58.
HiroseK, HamajimaN, TakezakiT, MiuraS, TajimaK. Physical exercise reduces risk of breast cancer in Japanese women. Cancer Sci, 2003; 94:193–199.
59.
FucicA, GamulinM, FerencicZ, et al.Environmental exposure to xenoestrogens and oestrogen related cancers: Reproductive system, breast, lung, kidney, pancreas, and brain. Environ Health, 2012; 11Suppl 1:S8.
60.
Ferlay.J, SoerjomataramI, ErvikM. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11, 2013. Available at: http://globocan.iarc.fr. Accessed November7, 2016.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
